2 Summary of Significant Accounting Policies



These consolidated financial statements were prepared in accordance with the International Financial Reporting Standards (IFRSIFRS: International Financial Reporting Standards; future EU-wide standards produced by the IASB) as published by the International Accounting Standards Board (IASB), London. The statements take into account the recommendations of the International Financial Reporting Standards Interpretations Committee (IFRS IC), as applicable in the European Union (EU) and also give consideration to the supplementary German commercial law provisions, applicable in accordance with Sec. 315a Para. 1 of the German Commercial Code (HGB).

These consolidated financial statements as of December 31, 2015 comprise MorphoSys AG and its subsidiaries (collectively referred to as the “MorphoSys Group” or the “Group”).

In preparing the consolidated financial statements in accordance with IFRS, the Management Board is required to make certain estimates and assumptions, which have an effect on the amounts recognized in the consolidated financial statements and the accompanying notes. The actual results may differ from these estimates. The estimates and the underlying assumptions are subject to continuous review. Any changes in estimates are recognized in the period in which the changes are made and in all relevant future periods.

The consolidated financial statements were prepared in euro – the MorphoSys Group’s functional currency. Statements are prepared on the basis of historical cost, except for derivative financial instruments and available-for-sale financial assets, which are recognized at their respective fair value. All figures in this report are rounded to the nearest euro, thousand euros or million euros.

Financial assets classified as loans and receivables were presented separately in 2015 for better transparency of the consolidated balance sheet. In the 2014 consolidated financial statements, these financial assets were included in other receivables. The prior year’s consolidated balance sheet was adjusted accordingly to ensure comparability.

In the consolidated statement of cash flows, interest paid and interest received were reclassified from operating activities into investing activities and financing activities. The prior year’s amounts were adjusted accordingly to ensure comparability.

For better transparency, the presentation of reserves in the balance sheet is divided into “Revaluation Reserve” and “Translation Reserve”.

Unless stated otherwise, the accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.


The accounting principles applied generally correspond to the policies used in the prior year.

The following new and revised standards and interpretations were applied for the first time in the financial year.

Standard/Interpretation Mandatory ­application for financial years starting on Adopted by the
European Union
Impact on
IFRIC 21 Levies 06/17/2014 yes none
Improvements to International Financial Reporting Standards,
2011 – 2013 cycle
01/01/2015 yes none

The following new and revised standards and interpretations, which were not yet mandatory for the financial year or were not yet adopted by the European Union, were not applied. Standards with the remark “yes” are likely to have an impact on the consolidated financial statements, and their impact is currently being assessed by the Group. Standards with the remark “none” are not likely to have a material impact on the consolidated financial statements.

Standard/Interpretation Mandatory ­application for financial years starting on Adopted by the
European Union
Possible impact on MorphoSys
IFRS 9 Financial Instruments 01/01/2018 no yes
IFRS 14 Regulatory Deferral Accounts 01/01/2016 no none
IFRS 15 Revenue from Contracts with Customers 01/01/2018 no yes
IFRS 16 Leases 01/01/2019 no yes
IFRS 10/12 and IAS 28 (A) Investment Entities – Applying the Consolidation Exception 01/01/2016 no none
IFRS 11 (A) Accounting for Acquisitions of Interests in Joint Operations 01/01/2016 yes none
IAS 1 (A) Disclosure Initiative 01/01/2016 yes yes
IAS 16 and IAS 38 (A) Clarification of Acceptable Methods of Depreciation and Amortization 01/01/2016 yes none
IAS 16 and IAS 41 (A) Bearer Plants 01/01/2016 yes none
IAS 19 (A) Defined Benefit Plans: Employee Contributions 02/01/2015 yes none
IAS 27 (A) Equity Method in Separate Financial Statements 01/01/2016 yes none
Improvements to International Financial Reporting Standards,
2010 – 2012 cycle
02/01/2015 yes none
Improvements to International Financial Reporting Standards,
2012 – 2014 cycle
01/01/2016 yes none
(A) Amended

The new IFRS 15 standard on revenue recognition was reviewed for its potential impact on the revenue recognition of existing contracts and future contracts with partners and/or licensees. The review for the existing contractual arrangements revealed that no material quantitative effects on the consolidated financial statements compared to the provision currently applied are to be expected. Qualitative adjustments of the required disclosures in the Notes under IFRS 15 will be expected, however they will not be made until the standard’s first-time application as of January 1, 2018.


Intercompany balances and transactions and any unrealized gains arising from intercompany transactions are eliminated when preparing consolidated financial statements pursuant to IFRS 10.B86. Unrealized losses are eliminated in the same manner as unrealized gains but are considered an indication of the transferred asset’s possible impairment. Accounting policies have been applied consistently for all subsidiaries.

For all contracts and business transactions between group entities the arm’s length principle was applied.


MorphoSys AG as ultimate parent company of the Group is located in Martinsried near Munich. MorphoSys AG has two wholly owned subsidiaries (collectively referred to as the “MorphoSys Group” or the “Group”): Sloning BioTechnology GmbH (Martinsried) and, as of May 7, 2015, Lanthio Pharma B.V. (Groningen, The Netherlands; see also Item 4 of these Notes). Additionally, MorphoSys AG’s investment in Lanthio Pharma B.V. indirectly gives it 100 % ownership in LanthioPep B.V. (Groningen, The Netherlands).

Poole Real Estate Ltd., Oxford, UK, was liquidated during the financial year 2015. The remaining assets were distributed to MorphoSys AG as the sole shareholder.


Company name and registered office
Share of
Capital %
Company Consolidated
(apart from Parent company)
Sloning BioTechnology GmbH, Martinsried, Germany 100
Lanthio Pharma B.V., Groningen, The Netherlands 100
LanthioPep B.V., Groningen, The Netherlands1 100

1 Indirect subsidiary via Lanthio Pharma B.V.

The consolidated financial statements for the year ended December 31, 2015 were prepared and approved by the Management Board in its meeting on February 16, 2016 by a resolution of the Management Board. The Management Board members are Dr. Simon Moroney (Chief Executive Officer), Jens Holstein (Chief Financial Officer), Dr. Marlies Sproll (Chief Scientific Officer), and Dr. Arndt Schottelius (Chief Development Officer). The Supervisory Board is authorized to amend the financial statements after their approval by the Management Board. MorphoSys Group’s headquarters are located at Lena-Christ-Straße 48, 82152 Martinsried, Germany.


The following Group subsidiaries are included in the scope of consolidation as shown in the following table.

Company Established in/ Purchase of Shares Included in ­Basis of Consolidation since
Sloning BioTechnology GmbH October 2010 10/07/2010
Lanthio Pharma B.V. May 2015 05/07/2015
LanthioPep B.V. May 2015 05/07/2015

These subsidiaries are fully consolidated because they are either directly or indirectly wholly owned. MorphoSys controls these subsidiaries because it possesses full power over the investees. Additionally, MorphoSys is subject to risk exposure or has rights to variable returns from its involvement with the investees. MorphoSys also has unlimited capacity to exert power over the investees to influence their returns.

The Group does not have any entities consolidated as joint ventures by using the equity method as defined by IFRS 11 “Joint Arrangements” nor does it exercise a controlling influence as defined by IAS 28 “Investments in Associates and Joint Ventures”. Interests in such entities would be measured at fair value or historic cost in accordance with IAS 39.

Assets and liabilities of fully consolidated domestic and international entities are recognized using Group-wide uniform accounting and valuation methods. The consolidation methods applied have not changed from the previous year.

Receivables, liabilities, expenses and income among consolidated entities are eliminated in the consolidated financial statements.


IAS 21 “The Effects of Changes in Foreign Exchange Rates” governs the accounting for transactions and balances denominated in foreign currencies. Transactions denominated in foreign currencies are translated at the exchange rates prevailing on the date of the transaction. Any resulting translation differences are recognized in profit and loss. On the reporting date, assets and liabilities are translated at the closing rate, and income and expenses are translated at the average exchange rate for the financial year. Any foreign exchange rate differences derived from these translations are recognized in the consolidated statement of income. Any other foreign exchange rate differences at the Group level are recognized in the “Translation Reserve” (stockholders’ equity).



Financial instruments that could subject the Group to a concentration of credit and liquidity risk consist primarily of cash, cash equivalents, marketable securities, derivative financial instruments and receivables. The Group’s cash and cash equivalents are principally denominated in euros. Marketable securities represent investments in high-quality securities. Cash, cash equivalents, and marketable securities are held at several renowned financial institutions in Germany. The Group continuously monitors its positions with financial institutions that are counterparts to its financial instruments and these institutions’ credit ratings and does not expect any risk of non-performance.

One of the Group’s policies requires all customers who wish to transact business on credit terms to undergo a credit assessment based on external ratings. Nevertheless, the Group’s revenues and accounts receivable are still subject to credit risk from customer concentration. The Group’s most significant single customer accounted for € 8.3 million of trade receivables as of December 31, 2015 (December 31, 2014: € 9.3 million). This customer accounted for 73 % of the Group’s accounts receivable at the end of 2015. Three individual customers of the Group accounted for 56 %, 39 %, and 2 % of the total revenues in 2015. On December 31, 2014, one customer had accounted for 62 % of the Group’s accounts receivable and three customers had individually accounted for 68 %, 21 %, and 3 % of the Group’s revenues in 2014. Based on the Management Board’s assessment, no allowances were required in the financial years 2015 and 2014. The carrying amounts of financial assets represent the maximum credit risk.

The table below shows the credit risk of trade receivables by region as of the reporting date.

in € 12/31/2015 12/31/2014
Europe and Asia 10,809,051 10,264,935
USA and Canada 633,008 4,725,597
Other 0 0
Total 11,442,059 14,990,532

The following table shows the term structure of trade receivables as of the reporting date.

in €; A/R are due since 12/31/2015
0 – 30 days
30 – 60 days
60+ days
Accounts Receivable 11,442,059 0 0 11,442,059
Write-off 0 0 0 0
Accounts Receivable, Net of Allowance for Impairment 11,442,059 0 0 11,442,059
in €; A/R are due since 12/31/2014
0 – 30 days
30 – 60 days
60+ days
Accounts Receivable 14,666,085 324,447 0 14,990,532
Write-off 0 0 0 0
Accounts Receivable, Net of Allowance for Impairment 14,666,085 324,447 0 14,990,532

As of December 31, 2015 and December 31, 2014, the Group was not exposed to a credit risk from derivative financial instruments. The maximum credit risk of financial guarantees (rent deposits) on the reporting date amounted to € 0.6 million (December 31, 2014: € 0.6 million).

The contractually agreed maturities and the corresponding cash outflows of accounts payable are within one year. Convertible bonds issued to related parties mature on March 31, 2020 (maximum cash outflow: € 0.2 million).


Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Group’s results of operations or the value of the financial instruments held. The Group is exposed to currency and interest rate risks.


The consolidated financial statements are prepared in euros. Whereas MorphoSys’s expenses are predominantly incurred in euros, a portion of the revenue is dependent on the prevailing exchange rate of the US dollar. Throughout the year, the Group monitors the need to hedge foreign exchange rates to minimize currency risk and addresses this risk by using derivative financial instruments.

The table below shows the Group’s exposure to foreign currency risk based on the items’ carrying amounts.

as of December 31, 2015; in € EUR USD Other Total
Cash and Cash Equivalents 90,206,933 720,740 0 90,927,673
Available-for-sale Financial Assets 64,292,830 0 0 64,292,830
Bonds, Available-for-sale 33,120,117 0 0 33,120,117
Financial Assets classified as Loans and Receivables 94,587,528 0 0 94,587,528
Financial Assets classified as Loans and Receivables, Net of Current Portion 15,510,989 0 0 15,510,989
Accounts Receivable 11,365,659 76,400 0 11,442,059
Accounts Payable and Accrued Expenses (22,308,082) (28,548) (5,033) (22,341,663)
Total 286,775,974 768,592 (5,033) 287,539,533
as of December 31, 2014; in € EUR USD Other Total
Cash and Cash Equivalents 32,130,970 107,191 0 32,238,161
Available-for-sale Financial Assets 106,039,373 0 0 106,039,373
Bonds, Available-for-sale 7,488,259 0 0 7,488,259
Financial Assets classified as Loans and Receivables 156,993,068 0 0 156,993,068
Financial Assets classified as Loans and Receivables, Net of Current Portion 50,030,000 0 0 50,030,000
Accounts Receivable 14,887,707 102,825 0 14,990,532
Accounts Payable and Accrued Expenses (17,763,146) (67,646) 0 (17,830,792)
Total 349,806,231 142,370 0 349,948,601

Various foreign exchange rates and their impact on assets and liabilities were simulated in an in-depth sensitivity analysis to determine the effects on income. A 10 % increase in the euro versus the US dollar as of December 31, 2015 would have reduced the Group’s income (assuming stable interest rates) by € 0.1 million. A 10 % decline in the euro versus the US dollar would have increased the Group’s income by € 0.1 million.

A 10 % increase in the euro versus the US dollar as of December 31, 2014 would have reduced the Group’s income by less than € 0.1 million (assuming stable interest rates). A 10 % decline in the euro versus the US dollar would have increased the Group’s income by less than € 0.1 million.

If the foreign exchange rates for the US dollar versus the euro had remained at the prior year’s average rate, the Group’s revenues would have been € 0.1 million lower. In 2014, Group revenues would have been € 0.1 million higher.


The Group’s risk exposure to changes in interest rates mainly relates to available-for-sale securities/investments. Changes in the general level of interest rates may lead to an increase or decrease in the fair value of these securities/investments. The Group’s investment focus places the safety of an investment ahead of its return. Interest rate risk is limited because all securities/investments can be liquidated within a maximum of two years.

The Group is not subject to significant interest rate risks from the liabilities currently reported in the balance sheet.


The IFRS 13 “Fair Value Measurement” guidelines must always be applied when measurement at fair value is required or permitted or disclosures regarding measurement at fair value are required based on another IAS/ IFRS guideline. The fair value is the price that would be achieved for the sale of an asset in an arm’s length transaction between independent market participants or the price to be paid for the transfer of a liability (disposal or exit price). Accordingly, the fair value of a liability reflects the default risk (i.e., own credit risk). Measurement at fair value requires that the sale of the asset or the transfer of the liability takes place on the principal market or, if no such principal market is available, on the most advantageous market. The principal market is the market a company has access to that has the highest volume and level of activity.

Fair value is measured by using the same assumptions and taking into account the same characteristics of the asset or liability as would an independent market participant. Fair value is a market-based, not an entity-specific measurement. The fair value of non-financial assets is based on the best use of the asset by a market participant. For financial instruments, the use of bid prices for assets and ask prices for liabilities is permitted but not required if those prices best reflect the fair value in the respective circumstances. For simplification, mean rates are also permitted. Thus, IFRS 13 not only applies to financial assets but all assets and liabilities.

MorphoSys uses the following hierarchy for determining and disclosing the fair value of financial instruments:

Level 1: Quoted (unadjusted) prices in active markets for identical assets or liabilities to which the Company has access.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly (i.e., as prices) or indirectly (i.e., derived from prices).

Level 3: Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, marketable securities, accounts receivable and accounts payable approximate their fair value because of their short-term maturities.


The fair value of financial instruments traded in active markets is based on the quoted market prices on the reporting date. A market is considered active if quoted prices are available from an exchange, dealer, broker, industry group, pricing service or regulatory body that is easily and regularly accessible and prices reflect current and regularly occurring market transactions at arm’s length conditions. For assets held by the Group, the appropriate quoted market price is the buyer’s bid price. These instruments fall under Level 1 of the hierarchy (see also Item 6.2 of these Notes).


The fair value of financial instruments not traded in active markets can be determined using valuation methods. In this case, fair value is estimated using the results of a valuation method that makes maximum use of market data and relies as little as possible on entity-specific inputs. If all inputs required for measuring fair value are observable, the instrument is allocated to Level 2. If important inputs are not based on observable market data, the instrument is allocated to Level 3.

Hierarchy level 2 contains the forward exchange contracts used for hedging. Future cash flows for these forward exchange contracts are based on forward curves. The fair value of these instruments is determined using discounted cash flows.

There were no financial assets or liabilities allocated to hierarchy level 3.

There were no transfers from one fair value hierarchy level to another in 2015 or 2014.

The table below shows the fair values of financial assets and liabilities and the carrying amounts presented in the consolidated balance sheet.





A financial instrument not carried at fair value through profit or loss is assessed at each reporting date to determine if there is objective evidence for impairment. A financial instrument is impaired if objective evidence indicates that an event has occurred after the initial recognition of the asset that could result in a loss and whether that event could have a negative effect on the asset’s estimated future cash flows, which can be assessed reliably.

Objective evidence that financial instruments (including equity securities) are impaired can include the default or delinquency of a debtor, indications that a debtor or issuer will enter insolvency, adverse changes in the payment status of borrowers or issuers in the Group as well as economic conditions that correlate with defaults or the disappearance of an active market for a security. A significant or prolonged decline in an equity security’s fair value below its acquisition cost is objective evidence of impairment.


The Group considers evidence of the impairment of receivables both on an individual and a collective level. All individually significant receivables are tested specifically for impairment. All individually significant receivables found not to be expressly impaired are then collectively tested for any impairment that occurred but was not yet identified. Individually non-significant receivables are collectively tested for impairment by grouping together receivables with similar risk characteristics.

In assessing collective impairment, the Group uses historical trends of default probabilities of the timing of impairment reversals and the amount of loss incurred. These are then adjusted to management’s assessment of whether current economic and credit conditions are such that the actual losses are likely to be greater or less than those suggested by historical trends.

For a financial instrument measured at amortized cost less impairment, impairment is calculated as the difference between its carrying amount and the present value of the estimated future cash flows. Cash flows are discounted at the asset’s initial effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account against receivables. Interest on the impaired asset continues to be recognized. When a subsequent event (e.g., repayment by a debtor) causes the amount of impairment to decrease, the impairment is reversed through profit and loss.


Impairment of available-for-sale financial assets is recognized by reclassifying the accumulated losses from the revaluation reserve in equity to profit and loss. The amount of the accumulated loss to be reclassified from equity to profit and loss is the difference between the acquisition cost less amortization and any principal repayment and the current fair value less any impairment previously recognized in profit or loss. If in a subsequent period the fair value of an impaired available-for-sale financial asset increases and this increase can be objectively linked to an event occurring after the impairment was recognized in profit or loss, then the impairment loss is reversed, and the amount of the reversal is recognized in profit or loss. Any subsequent increase in the fair value of an available-for-sale financial instrument is recognized under equity in other comprehensive income.


The carrying amounts of the Group’s non-financial assets, inventories and deferred tax assets are reviewed at each reporting date for any indication of impairment. The asset’s recoverable amount is estimated if such indication exists. For goodwill and intangible assets that have indefinite useful lives or are not yet available for use, the recoverable amount is estimated at the same time each year. Impairment is recognized if the carrying amount of an asset or the cash-generating unit (CGU) exceeds its estimated recoverable amount.

The recoverable amount of an asset or CGU is the greater of its value-inuse or its fair value less costs of disposal. In assessing value-in-use, the estimated future pre-tax cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. For the purposes of impairment testing, assets that cannot be tested individually are grouped into the smallest group of assets that generates cash flows from ongoing use that are largely independent of the cash flows of other assets or CGUs. A ceiling test for the operating segment must be carried out for goodwill impairment testing. CGUs that have been allocated goodwill aggregated so that the level at which impairment testing is performed reflects the lowest level at which goodwill is monitored for internal reporting purposes. Goodwill acquired in a business combination is allocated to groups of CGUs that are expected to benefit from the combination’s synergies.

The Group’s corporate assets do not generate separate cash flows and are utilized by more than one CGU. Corporate assets are allocated to CGUs on a reasonable and consistent basis and are tested for impairment as part of the impairment testing of the CGU that was allocated the corporate asset.

Impairment losses are recognized in profit and loss. Goodwill impairment cannot be reversed. For all other assets, impairment recognized in prior periods is assessed on each reporting date for any indications that the losses decreased or no longer exist. Impairment is reversed when there has been a change in the estimates used to determine the recoverable amount. Impairment losses can only be reversed to the extent that the asset’s carrying amount does not exceed the carrying amount net of depreciation or amortization that would have been determined if an impairment had not been recognized.



Estimates and judgments are continually evaluated and based on historical experience and other factors that include expectations of future events that are believed to be realistic under the prevailing circumstances.

The Group makes estimates and assumptions concerning the future. The resulting accounting-related estimates will, by definition, seldom correspond to the actual results. The estimates and assumptions that carry a significant risk of causing material adjustments to the carrying amounts of assets and liabilities in the next financial year are addressed below.


The Group performs a yearly test to determine whether goodwill is subject to impairment in accordance with the accounting policies discussed in Item 2.4.4*. The recoverable amounts from cash-generating units have been determined using value-in-use calculations and are subjected to a sensitivity analysis. These calculations require the use of estimates (see also Item 6.7.5* of the Notes).


The Group is subject to income taxes in a number of tax jurisdictions. Due to the increasing complexity of the income tax law and the corresponding uncertainty regarding the legal interpretation by the fiscal authority tax calculations are generally subject to an increasing amount of uncertainty. Where necessary, possible tax risks are taken into account in the form of a provision.

As of December 31, 2015, deferred tax assets on tax loss carryforwards in the amount of € 1.2 million (December 31, 2014: € 1.8 million) were recognized as a result of profits expected from Sloning BioTechnology GmbH in financial years 2016 to 2020.

As of December 31, 2015, no deferred tax assets on tax loss carryforwards in the amount of € 8.6 million were recognized as a result of losses expected from the Lanthio Group in financial years 2016 to 2020.


The Management Board’s policy for capital management is to preserve a strong and sustainable capital base in order to maintain the confidence of investors, business partners, and the market and to support future business development. As of December 31, 2015, the equity ratio was 90.7 % (December 31, 2014: 81.8 %; see also the following overview). The Group does not currently have any financial debt.

Under the respective incentive plans resolved by the Annual General Meeting, the Management Board and employees may participate in the Group’s performance through long-term performance-related remuneration consisting of convertible bonds. MorphoSys also established longterm incentive programs (LTI plan) in 2011, 2012, 2013, 2014 and 2015. These programs are based on the performance-related issue of shares, or “performance shares”, which are granted when certain predefined success criteria have been achieved (for more information, please refer to Item 8.2 of the Notes). There were no changes in the Group’s approach to capital management during the year.

in 000’ € 12/31/2015 12/31/2014
Stockholders’ Equity 362,736 348,803
In % of Total Capital 90.7 % 81.8 %
Debt 37,343 77,675
In % of Total Capital 9.3 % 18.2 %
Total Capital 400,079 426,478


The Group uses interest rates to measure fair value. When calculating stockbased compensation, MorphoSys uses interest rates on German government bonds with maturities of five or seven years on the date they were granted to determine the fair value of convertible bonds.



The Group’s revenue includes license fees, milestone payments, service fees and revenues from the sale of goods. Under IAS 18.9, revenues are measured at the fair value of the consideration received or receivable. In accordance with IAS 18.20b, revenues are recognized only to the extent that it is sufficiently probable that the Company will receive the economic benefits associated with the transaction.


Revenues related to non-refundable fees for providing access to technologies, fees for the use of technologies and license fees are recognized on a straight-line basis over the period of the agreement unless a more appropriate method of revenue recognition is available. The period of the agreement usually corresponds to the contractually agreed term of the research project or, in the case of contracts without an agreed project term, the expected term of the collaboration. If all IAS 18.14 criteria are met, revenue is recognized immediately and in full. Revenues from milestone payments are recognized upon achievement of certain contractual criteria.


Service fees from research and development collaborations are recognized in the period the services are provided.

Discounts that are likely to be granted and whose amount can be reliably determined are recognized as a reduction in revenue at the time of revenue recognition. The timing of the transfer of risks and rewards varies depending on the terms of the sales contract. In accordance with IAS 18.21 and 18.25, revenue from multiple-component contracts is recognized by allocating the total consideration to the separately identifiable components based on their respective fair values and by applying IAS 18.20. The applicable revenue recognition criteria are assessed separately for each component.

Deferred revenue consist of customer payments that were not yet recognized as revenue because the related services specified in the contract were not yet rendered.



The Group applies the provisions of IFRS 2 “Share-based Payment”, which require the Group to recognize as a compensation expense share-based payments at their fair value on the value date for the period in which the beneficiaries provide the services related to granting the share-based payments.


Research costs are expensed in the period they occur. Development costs are generally expensed as incurred in accordance with IAS 38.5 and IAS 38.11 to 38.23. Development costs are recognized as an intangible asset when the criteria of IAS 38.21 (probability of expected future economic benefits, reliability of cost measurement) are met and if the Group can provide proof under IAS 38.57.


This line item contains personnel expenses, consumables, operating costs, amortization of intangible assets, expenses for external services, infrastructure costs and depreciation.


Payments made under operating leases are recognized in the income statement on a straight-line basis over the term of the lease. According to SIC-15, all incentive agreements in the context of operating leases are recognized as an integral part of the net consideration agreed for the use of the leased asset. The total amount of income from incentives is recognized as a reduction in lease expenses on a straight-line basis over the term of the lease.

All of the Group’s lease agreements are classified exclusively as operating leases. The Group did not engage in any finance lease arrangements in which the Group, as lessee, capitalized the assets at the start of the lease at the lower of fair value or the net present value of the minimum-lease payments and then depreciated the assets on a straight-line basis over their economic life.



Grants received from government agencies to fund specific research and development projects are recognized in the income statement in the separate line item “other income” to the extent that the related expenses have already occurred. Under the terms of the grants, government agencies generally have the right to audit the use of the funds granted to the Group.

Basically, government grants are cost subsidies, and their recognition through profit and loss is limited to the corresponding costs. No payments were granted in the 2015 financial year that are required to be classified as investment subsidies.


The line item “other expenses” consists mainly of currency losses from the operating business.


Interest income is recognized in the income statement as it occurs and takes into account the asset’s effective interest rate.


Borrowing costs are expensed in the period they occur and included in finance expenses in the income statement.


Income taxes consist of current and deferred taxes and are recognized in the income statement unless they relate to items recognized directly in equity or other comprehensive income.

Current taxes are the taxes expected to be payable on the year’s taxable income based on prevailing tax rates on the reporting date and any adjustments to taxes payable in previous years.

The calculation of deferred taxes is based on the balance sheet liability method and results in temporary differences between the carrying amounts of assets and liabilities and the amounts used for taxation purposes. The method of calculating deferred taxes depends on how the asset’s carrying amount is expected to be realized and how the liabilities will be repaid. The calculation is based on the prevailing tax rates or those adopted on the reporting date.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax liabilities and assets and when they relate to income taxes imposed on the same taxable entity by the same tax authority or on different tax entities that intend to settle the balance of current tax assets and liabilities on a net basis or when the tax assets and liabilities are to be realized simultaneously.

Deferred tax assets are recognized only to the extent that it is likely that there will be future taxable income to offset. Deferred tax assets are reduced by the amount that the related tax benefit is no longer expected to be realized.


The Group reports basic and diluted earnings per share. Basic earnings per share is computed by dividing the net profit or loss attributable to parent company shareholders by the weighted average number of ordinary shares outstanding during the reporting period. Diluted earnings per share is calculated in the same manner with the exception that the net profit or loss attributable to parent company shareholders and the weighted average number of ordinary shares outstanding are adjusted for any dilutive effects resulting from convertible bonds granted to the Management Board and employees.




The Group defines liquid assets as all cash at banks and on hand and all short-term deposits with an original maturity of three months or less. The Group invests most of its liquid assets at several major financial institutions: Commerzbank, UniCredit, Bayern LB, LBBW, BNP Paribas, Deutsche Bank and Rabobank.

The Group recognizes liquid assets at their nominal value. Securities are recognized and measured at fair value. Any fluctuations in the fair value of securities consisting mainly of money market funds are directly recognized in equity. Permanent impairment is recognized in profit and loss.


Depending on how they are classified, existing financial instruments are either measured at amortized cost (category “loans and receivables”) or fair value (category “available-for-sale financial assets”). The amortized cost of current receivables and current liabilities generally corresponds to either the nominal amount or repayment amount.

All non-derivative financial instruments are initially recognized at fair value, which is defined as the fair value of the consideration provided net of transaction costs.

The Group applies IAS 39 for financial instruments in the form of debt and equity instruments. At the time of purchase, the Management Board determines the financial instrument’s classification and reviews this classification at each reporting date. The classification depends on the purpose of acquiring the financial instrument. As of December 31, 2015 and December 31, 2014, some financial instruments held by the Group were classified as “available-for-sale”. These financial instruments are recognized or derecognized as of the date on which the Group commits to the financial instrument’s purchase or sale. Following their initial recognition, available- for-sale financial assets are measured at fair value, and any resulting gain or loss is reported directly in the revaluation reserve within equity until the financial instruments are sold, redeemed, otherwise disposed of or considered impaired, at which time the accumulated loss is reported in profit and loss.

Guarantees granted for rent deposits that have been collateralized with available-for-sale securities and obligations from convertible bonds issued to employees are recorded under other assets as restricted cash since they are not available for use in the Group’s operations.


The Group uses derivative financial instruments to hedge its exposure to foreign exchange rate risk. In accordance with IAS 39.9, all derivative financial instruments are held exclusively for trading and are initially recognized at fair value. After their initial recognition, derivative financial instruments are measured at fair value, which is defined as their quoted market price on the reporting date. Any resulting gain or loss from derivatives is recognized in profit and loss because the Group currently does not apply hedge accounting. According to the Group’s foreign currency hedging policy, the Group only hedges highly probable future cash flows and clearly identifiable receivables that can be collected within a 24-month period.

The use of derivative financial instruments is subject to a Group policy that is a written guideline approved by the Management Board for dealing with derivative financial instruments. Any changes in the fair value of derivative financial instruments are documented.


Accounts receivable are measured at amortized cost less any impairment; for example, allowances for doubtful accounts (see Items 2.4.2 and 6.3 of the Notes).

Income tax receivables mainly include receivables due from tax authorities in the context of capital gain taxes withheld.

Other non-derivative financial instruments are measured at amortized cost using the effective interest method less any impairment.


Inventories are measured at the lower value of production or acquisition cost and net realizable value under the FIFO method. Acquisition costs comprise all costs of purchase and those incurred in bringing the inventories into operating condition while taking into account purchase price reductions, such as bonuses and discounts. Net realizable value is the estimated selling price less the estimated expenses necessary for completion and sale. Inventories are divided into the categories of raw materials and supplies.


Prepaid expenses include expenses resulting from an outflow of liquid assets prior to the reporting date that are only recognized as expenses in the subsequent financial year. Such expenses usually involve maintenance contracts, sublicenses and prepayments for external laboratory services not yet performed. Other current assets primarily consist of receivables from tax authorities resulting from value-added taxes. This item is recognized at nominal value.


Property, plant and equipment is recorded at historical cost less accumulated depreciation (see also Item 6.6* of the Notes) and any impairment (see Item 2.4.4 of the Notes). Historical cost includes expenditures directly related to the purchase at the time of the acquisition. Replacements purchases, building alterations and improvements are capitalized while repair and maintenance expenses are charged as expenses as they are incurred. Property, plant and equipment is depreciated on a straight-line basis over its useful life (see table below). Leasehold improvements are depreciated on a straight-line basis over the asset’s estimated useful life.

Asset Class Useful Life Depreciation Rates
Computer Hardware 3 years 33 %
Low-value Laboratory and Office Equipment below € 410 Immediately 100 %
Permanent Improvements to ­Property/Buildings 10 years 10 %
Office Equipment 8 years 13 %
Laboratory Equipment 4 years 25 %

Asset’s residual values and useful lives are reviewed at the end of each reporting period and adjusted if appropriate.

Borrowing costs that can be directly attributed to the acquisition, construction or production of a qualifying asset are not included in the acquisition or production costs because the Group finances the entire operating business with equity.


Purchased intangible assets are capitalized at acquisition cost and exclusively amortized on a straight-line basis over their useful lives. Internally generated intangible assets are recognized to the degree the recognition criteria set out in IAS 38 are met.

Development costs are capitalized as intangible assets when the capitalization criteria described in IAS 38 have been met, namely, clear specification of the product or procedure, technical feasibility, intention of completion, use, commercialization, coverage of development costs through future free cash flows, reliable determination of these free cash flows and availability of sufficient resources for completion of development and sale. Amortization is recorded in research and development expenses.

Expenses to be classified as research expenses are allocated to research and development expenses as defined by IAS 38.

Subsequent expenditures for capitalized intangible assets are capitalized only when they substantially increase the future economic benefits of the specific asset to which they relate. All other expenditures are expensed as incurred.


Patents obtained by the Group are recorded at acquisition cost less accumulated amortization (see below) and any impairment (see Item 2.4.4 of the Notes). Patent costs are amortized on a straight-line basis over the lower of the estimated useful life of the patent (ten years) or the remaining patent term. Amortization starts when the patent is issued. Technology identified in the purchase price allocation for the acquisition of Sloning BioTechnology GmbH is recorded at the fair value at the time of acquisition, less accumulated amortization (useful life of ten years).


The Group has acquired license rights from third parties by making upfront license payments, paying annual fees to maintain the license and paying fees for sub-licenses. The Group amortizes upfront license payments on a straight-line basis over the estimated useful life of the acquired license (eight to ten years). The amortization period and method are reviewed at the end of each financial year under IAS 38.104. Annual fees to maintain a license are amortized over the term of each annual agreement. Sub-license fees are amortized on a straight-line basis over the term of the contract or the estimated useful life of the collaboration for contracts without a set duration.


This line item contains capitalized upfront payments from the in-licensing of two compounds for the Proprietary Development segment as well as a milestone payment for one of these compounds which was paid at a later time. Additionally, two compounds are included resulting from an acquisition. The assets are recorded at acquisition cost and are not yet available for use and therefore not subject to amortization. The assets were tested for impairment on the reporting date as required by IAS 36.


Software is recorded at acquisition cost less accumulated amortization (see below) and any impairment. Amortization is recognized in profit and loss on a straight-line basis over the estimated useful life of three to five years. Software is amortized from the date the software is operational.


Goodwill is recognized for expected synergies from business combinations and the skills of the acquired workforce. Goodwill is tested annually for impairment as required by IAS 36.

Intangible Asset Class Useful Life Amortisation Rates
Patents 10 years 10 %
License Rights 8 –10 years 13 % – 10 %
In-process R&D Programs Not yet amortized
Software 3 – 5 years 33 % – 20 %
Goodwill Impairment Only


The 19.98 % interest in Dutch Lanthio Pharma B.V. was recognized at amortized cost and recorded as a financial instrument under the category “available-for-sale” in the prior year. Following the acquisition of all outstanding shares of Lanthio Pharma B.V. on May 7, 2015, the entity was fully included in MorphoSys’ consolidated financial statements.


The non-current portion of expenses that occurred prior to the reporting date but to be recognized in subsequent financial years is also recorded under prepaid expenses. This line item contains maintenance contracts and sublicenses.

This line item also includes other non-current assets, which are recognized at fair value. Other non-current assets consist mainly of restricted cash, such as rent deposits.



Trade payables and other liabilities are recognized at amortized cost. Liabilities with a term of more than one year are discounted to their net present value. Liabilities with uncertain timing or amount are recorded as provisions.

IAS 37 requires the recognition of provisions for obligations to third parties arising from past events. Furthermore, provisions are only recognized for legal or factual obligations to third parties if the event’s occurrence is more likely than not. Provisions are recognized at the amount required to settle the respective obligation and discounted to the reporting date if the interest effect is material. The amount required to meet the obligation also includes expected price and cost increases. The interest portion of the added provisions is recorded in the finance result. The measurement of provisions is based on past experience and considers the circumstances in existence on the reporting date.


Tax liabilities are recognized and measured at their nominal value. Tax liabilities contain obligations from current taxes, excluding deferred taxes. Provisions for trade taxes, corporate taxes and similar taxes on income are determined based on the taxable income of the consolidated companies less any prepayments made.


Upfront payments from customers for services to be rendered by the Group are recognized as deferred revenue in accordance with IAS 18.13 and measured at the lower of fair or nominal value. The corresponding rendering of services and revenue recognition occurs within the 12-month period following the reporting date.


This line item includes the non-current portion of deferred upfront payments from customers in accordance with IAS 18.13, which are measured at the lower of fair or nominal value. Due to its low materiality, this line item is not discounted to its present value in the financial year despite its long-term maturity.


The Group issued convertible bonds to the Group’s Management Board and employees. In accordance with IAS 32.28, the equity component of a convertible bond must be recorded separately under additional paid-in capital. The equity component is determined by deducting the separately determined amount of the liability component from the fair value of the convertible bond. The effect of the equity component is recognized in profit and loss in personnel expenses from share-based payments, whereas the effect on profit and loss from the liability component is recognized as interest expense. The Group applies the provisions of IFRS 2 “Share-based Payments” for all convertible bonds granted to the Management Board and the Group’s employees.


The recognition and measurement of deferred taxes are based on the provisions of IAS 12. Deferred tax assets and liabilities are calculated using the liability method, which is common practice internationally. Under this method, taxes expected to be paid or recovered in subsequent financial years are based on the applicable tax rate at the time of recognition.

Deferred tax assets and liabilities are recorded separately in the balance sheet. Deferred tax liabilities take into account the future tax effects of temporary differences between the value of assets and liabilities in the balance sheet and tax loss carryforwards.

Deferred tax assets are offset against deferred tax liabilities if the taxes are levied by the same taxation authority and have matching terms. Pursuant to IAS 12, deferred tax assets and liabilities may not be discounted.



Ordinary shares are classified as stockholders’ equity. Incremental costs directly attributable to the issue of ordinary shares and stock options are recognized as a deduction from stockholders’ equity, net of any tax effects. When common stock that was recorded as stockholders’ equity is repurchased, the amount of consideration paid, including directly attributable costs, is recognized as a deduction from stockholders’ equity net of taxes and is classified as treasury shares. When treasury shares are subsequently sold or reissued, the proceeds are recognized as an increase in stockholders’ equity, and the profit or loss resulting from the transaction is offset against accumulated income.


Repurchases of the Company’s own shares at prices quoted on an exchange or at market value are recorded in this line item.


Additional paid-in capital mainly consists of personnel expenses resulting from the grant of convertible bonds and performance shares and the proceeds from newly created shares in excess of their nominal value.


The revaluation reserve mainly consists of unrealized gains and losses on available-for-sale securities that are measured directly in equity until they are sold.


The translation reserve comprises all foreign exchange differences that are not recognized in profit and loss.


The “accumulated income” line item consists of the Group’s accumulated consolidated net profits/losses. A separate measurement of this item is not made.

Top Previous Next